These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 35766879)
21. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N. Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646 [TBL] [Abstract][Full Text] [Related]
22. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease. Chen X; Tsika E; Levine N; Moore DJ Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299 [TBL] [Abstract][Full Text] [Related]
23. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854 [TBL] [Abstract][Full Text] [Related]
24. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203 [TBL] [Abstract][Full Text] [Related]
25. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant. Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683 [TBL] [Abstract][Full Text] [Related]
26. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632 [TBL] [Abstract][Full Text] [Related]
27. In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Wang HS; Toh J; Ho P; Tio M; Zhao Y; Tan EK Mol Brain; 2014 Oct; 7():73. PubMed ID: 25288323 [TBL] [Abstract][Full Text] [Related]
28. Dopamine-dependent, swimming-induced paralysis arises as a consequence of loss of function mutations in the RUNX transcription factor RNT-1. Robinson SB; Refai O; Hardaway JA; Sturgeon S; Popay T; Bermingham DP; Freeman P; Wright J; Blakely RD PLoS One; 2019; 14(5):e0216417. PubMed ID: 31083672 [TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Sargent D; Moore DJ Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708 [TBL] [Abstract][Full Text] [Related]
30. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Malik BR; Godena VK; Whitworth AJ Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041 [TBL] [Abstract][Full Text] [Related]
31. The Role of VPS35 in the Pathobiology of Parkinson's Disease. Sassone J; Reale C; Dati G; Regoni M; Pellecchia MT; Garavaglia B Cell Mol Neurobiol; 2021 Mar; 41(2):199-227. PubMed ID: 32323152 [TBL] [Abstract][Full Text] [Related]
32. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex. Macías-Calvio V; Fuentealba LM; Marzolo MP J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426 [TBL] [Abstract][Full Text] [Related]
33. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562 [TBL] [Abstract][Full Text] [Related]
34. Contributions of VPS35 Mutations to Parkinson's Disease. Rahman AA; Morrison BE Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673 [TBL] [Abstract][Full Text] [Related]
35. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress. McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383 [TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy. Ma KY; Fokkens MR; Reggiori F; Mari M; Verbeek DS Transl Neurodegener; 2021 Jun; 10(1):19. PubMed ID: 34127073 [TBL] [Abstract][Full Text] [Related]
37. Role of the VPS35 D620N mutation in Parkinson's disease. Mohan M; Mellick GD Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832 [TBL] [Abstract][Full Text] [Related]
38. VPS35, the Retromer Complex and Parkinson's Disease. Williams ET; Chen X; Moore DJ J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice. Bu M; Follett J; Deng I; Tatarnikov I; Wall S; Guenther D; Maczis M; Wimsatt G; Milnerwood A; Moehle MS; Khoshbouei H; Farrer MJ NPJ Parkinsons Dis; 2023 Dec; 9(1):167. PubMed ID: 38110354 [TBL] [Abstract][Full Text] [Related]
40. D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population. Kalinderi K; Bostantjopoulou S; Katsarou Z; Dimikiotou M; Fidani L Neurosci Lett; 2015 Oct; 606():113-6. PubMed ID: 26300542 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]